Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid

AIDS Research and Human Retroviruses

Volumn 25, Issue 2, 2009, Pages 207-212

  Archin, Nancie M ^a   Espeseth, Amy ^b   Parker, Daniel ^a   Cheema, Manzoor ^a   Hazuda, Daria ^b   Margolis, David M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ENHANCED GREEN FLUORESCENT PROTEIN; VORINOSTAT;

ARTICLE; CD4+ T LYMPHOCYTE; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NUCLEOSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS GENOME;

CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CELLS, CULTURED; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HISTONE DEACETYLASES; HIV INFECTIONS; HIV-1; HUMANS; HYDROXAMIC ACIDS; VIRUS ACTIVATION; VIRUS REPLICATION;

EID: 60849127627     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0191     Document Type: Article

References (38)

1. Wong JK, Hezareh M, Gunthard HF, et al.: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-1295.
2. Finzi D, Hermankova M, Pierson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-1300.
3. Chun TW, Stuyver L, Mizell SB, et al.: Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997;94:13193-13197.
4. Pazin MJ, Sheridan PL, Cannon K, et al.: NF-kappa B-mediated chromatin reconfiguration and transcriptional activation of the HIV-1 enhancer in vitro. Genes Dev 1996; 10:37-49.
5. Van Lint C, Emiliani S, Ott M, and Verdin E: Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J 1996;15:1112-1120.
6. El Kharroubi A, Piras G, Zensen R, and Martin MA: Transcriptional activation of the integrated chromatin-associated human immunodeficiency virus type 1 promoter. Mol Cell Biol 1998;18:2535-2544.
7. Jenuwein T and Allis CD. Translating the histone code. Science 2001;293:1074-1080.
8. Strahl BD and Allis CD: The language of covalent histone modifications. Nature 2000;403:41-45.
9. Gregory PD, Wagner K, and Horz W: Histone acetylation and chromatin remodeling. Exp Cell Res 2001;265:195-202.
10. Davie JR: Covalent modifications of histones: Expression from chromatin templates. Curr Opin Genet Dev 1998;8:173-178.
11. Turner BM: Histone acetylation and an epigenetic code. BioEssays 2000;22:836-845.
12. Turner BM: Histone acetylation as an epigenetic determinant of long-term transcriptional competence. Cell Mol Life Sci 1998;54:21-31.
13. Mai A, Massa S, Rotili D, et al.: Histone deacetylation in epigenetics: An attractive target for anticancer therapy. Med Res Rev 2005;25:261-309.
14. Norton VG, Imai BS, Yau P, and Bradbury EM: Histone acetylation reduces nucleosome core particle linking number change. Cell 1989;57:449-457.
15. Margolis DM, Somasundaran M, and Green MR: Human transcription factor YY1 represses human immunodeficiency virus type 1 transcription and virion production. J Virol 1994;68:905-910.
16. Romerio F, Gabriel MN, and Margolis DM: Repression of human immunodeficiency virus type 1 through the novel cooperation of human factors YY1 and LSF. J Virol 1997;71:9375-9382.
17. Coull JJ, Romerio F, Sun JM, et al.: The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol 2000;74:6790-6799.
18. He G and Margolis DM: Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator tat. Mol Cell Biol 2002;22:2965-2973.
19. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, and Greene WC: NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J 2006;25:139-149.
20. Jiang G, Espeseth A, Hazuda DJ, and Margolis DM: c-myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol 2007;81:10914-10923.
21. Tyagi M and Karn J: CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J 2007;26:4985-4995.
22. Ylisastigui L, Coull JJ, Rucker VC, et al.: Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors. J Infect Dis 2004;190:1429-1437.
23. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, and Margolis DM: Coaxing HIV-1 from resting CD4 T cells: Histone deacetylase inhibition allows latent viral expression. AIDS 2004;18:1101-1108.
24. Quivy V, Adam E, Collette Y, et al.: Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-kappaB and inhibitors of deacetylases: Potential perspectives for the development of therapeutic strategies. J Virol 2002;76:11091-11103.
25. Lehrman G, Hogue IB, Palmer S, et al.: Depletion of latent HIV-1 infection in vivo: A proof-of-concept study. Lancet 2005;366:549-555.
26. Siliciano JD, Lai J, Callender M, et al.: Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis 2007;195:833-836.
27. Archin NM, Eron JJ, Palmer S, et al.: Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS 2008;22:1131-1135.
28. Sagot-Lerolle N, Lamine A, Chaix ML, et al.: ANRS EP39 study. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS 2008;22:1125-1129.
29. Marks PA: Discovery and development of SAHA as an anticancer agent. Oncogene 2007;26:1351-1356.
30. Marks PA and Breslow R: Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007;25:84-90.
31. Mann BS, Johnson JR, Cohen MH, Justice R, and Pazdur R: FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12:1247-1252.
32. Marban C, Suzanne S, Dequiedt F, de Walque S, Redel L, Van Lint C, Aunis D, and Rohr O: Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing EMBO J 2007;26:412-423.
33. Kutsch O, Benveniste EN, Shaw GM, and Levy DN: Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency. J Virol 2002;76:8776-8786.
34. Klichko V, Archin N, Kaur R, Lehrman G, and Margolis D: Hexamethylbisacetamide remodels the human immunodeficiency virus type 1 (HIV-1) promoter and induces Tat-independent HIV-1 expression but blunts cell activation. J Virol 200;80:4570-4579.
35. Jordan A, Defechereux P, and Verdin E: The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to tat transactivation. EMBO J 2001;20:1726-1738.
36. Myers LE, McQuay LJ, and Hollinger FB: Dilution assay statistics. J Clin Microbiol 1994;32:732-739.
37. Butler LM, Agus DB, Scher HI, et al.: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000;60:5165-5170.
38. Yamagoe S, Kanno T, Kanno Y, et al.: Interaction of histone acetylases and deacetylases in vivo. Mol Cell Biol 2003;23: 1025-1033.